The Cooper Companies (COO) stock plunged after reporting disappointing Q3 results, issuing weak Q4 and full-year guidance, and deciding against selling its CooperSurgical unit. The negative financial performance and outlook, coupled with the strategic review outcome, are driving significant investor concern.
The Cooper Companies experienced a significant after-hours stock drop due to a confluence of negative factors. Its fiscal third-quarter revenue growth was minimal (1%), and non-GAAP EPS only rose 4%, with key CooperVision segments showing organic declines. More critically, the company issued a weaker-than-expected outlook for both Q4 and the full fiscal year 2026, signaling continued headwinds, particularly from reduced U.S. channel inventory. Furthermore, the completion of its strategic review, which concluded with the decision to retain CooperSurgical rather than sell it, disappointed some investors who may have anticipated a value-unlocking transaction. This combination of underperformance and a less-than-ideal strategic outcome creates significant short-term pressure on the stock, with long-term implications depending on the company's ability to reverse current trends and improve its guidance.